Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck
Summary
Cetuximab in combination with platinum-based chemotherapy is not recommended for people with recurrent and/or metastatic squamous cell cancer of the head and neck. Healthcare professionals should not stop prescribing cetuximab in combination with platinum-based chemotherapy for people who were alre ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in June 2012
About this guidance
Technology appraisals TA172
Issued: June 2009
How this guidance was produced